Gastrointestinal Stromal Tumor (GIST) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Gastrointestinal stromal tumors (GIST) belong to a group of cancers called soft tissue sarcoma. GISTs can be benign or malignant tumors. Its treatment involves the use of surgery, radiation therapy, targeted therapy, and chemotherapy.

The Gastrointestinal Stromal Tumor pipeline market research report provides comprehensive information on the therapeutics under development for GIST, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for GIST and features dormant and discontinued projects.

GIST Pipeline Products Market Segmentation by Targets

The key targets in the GIST pipeline products market are Mast/Stem Cell Growth Factor Receptor Kit, Platelet Derived Growth Factor Receptor Alpha, Platelet Derived Growth Factor Receptor Beta, Vascular Endothelial Growth Factor Receptor 2, Vascular Endothelial Growth Factor Receptor 3, Programmed Cell Death Protein 1, Receptor Type Tyrosine Protein Kinase FLT3, Serine/Threonine Protein Kinase B Raf, Vascular Endothelial Growth Factor Receptor 1, and Fibroblast Growth Factor Receptor 1, among others.

GIST Pipeline Products Market Analysis by Targets

For more target insights into the GIST Pipeline Products Market, download a free report sample

GIST Pipeline Products Market Segmentation by Mechanisms of Action

The key mechanisms of action in the GIST pipeline products market are Mast/Stem Cell Growth Factor Receptor Kit Inhibitor, Platelet Derived Growth Factor Receptor Alpha Inhibitor, Vascular Endothelial Growth Factor Receptor 2 Inhibitor, Vascular Endothelial Growth Factor Receptor 3 Inhibitor, Platelet Derived Growth Factor Receptor Beta Inhibitor, Programmed Cell Death Protein 1 Antagonist, Receptor Type Tyrosine Protein Kinase FLT3 Inhibitor, Serine/Threonine Protein Kinase B Raf Inhibitor, Vascular Endothelial Growth Factor Receptor 1 Inhibitor, and Cytotoxic To Cells Expressing Mast/Stem Cell Growth Factor Receptor Kit, among others.

GIST Pipeline Products Market Analysis by MoA

For more MoA insights into the GIST Pipeline Products Market, download a free report sample

GIST Pipeline Products Market Segmentation by Routes of Administration

The key routes of administration in the GIST pipeline products market are oral, intravenous, subcutaneous, parenteral, intratumor, intravenous drip, inhalational, intradermal, intravesical, and ophthalmic.

GIST Pipeline Products Market Analysis by RoA

For more RoA insights into the GIST Pipeline Products Market, download a free report sample

GIST Pipeline Products Market Segmentation by Molecule Types

The key molecule types in the GIST pipeline products market are small molecule, monoclonal antibody, monoclonal antibody conjugated, cell therapy, oncolytic virus, synthetic peptide, antisense oligonucleotide, gene-modified cell therapy, oligonucleotide, peptide, and recombinant protein.

GIST Pipeline Products Market Analysis by Molecule Types

For more molecule type insights into the GIST Pipeline Products Market, download a free report sample

GIST Pipeline Products Market - Competitive Landscape

Some of the leading companies in the GIST pipeline products market are Novartis AG, Bayer AG, Blueprint Medicines Corp, Advenchen Laboratories LLC, Ascentage Pharma Group International, CStone Pharmaceuticals Co Ltd, IDRx Inc, Novelty Nobility Inc, Pfizer Inc, and AB Science SA.

GIST Pipeline Products Market Analysis by Companies

To know more about the leading players in the GIST Pipeline Products Market, download a free report sample

GIST Pipeline Products Market Report Overview

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Gastrointestinal Stromal Tumors (GIST) (Oncology).
• The pipeline guide reviews pipeline therapeutics for Gastrointestinal Stromal Tumor (GIST) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Gastrointestinal Stromal Tumor (GIST) (Oncology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Gastrointestinal Stromal Tumor (GIST) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews the latest news related to pipeline therapeutics for Gastrointestinal Stromal Tumor (Oncology)

Reasons to Buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Gastrointestinal Stromal Tumor (GIST) (Oncology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Gastrointestinal Stromal Tumor (GIST) (Oncology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.